Citations

Clear

4564 citation(s) found for "Yu, Virginia".

High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series
Zayac, Adam , Bock, Allison M. , Nowakowski, Grzegorz S. , Ayers, Emily C. , Girton, Mark , Hu, Marie , Beckman, Amy , Li, Shaoying , Chang, Julie E , Sandoval‐Sus, Jose , Ansari‐Lari, M. Ali, Kothari, Shalin , Kress, Anna, Xu, Mina L. , Torka, Pallawi , Smith, Stephen D. , Naresh, Kikkeri N. , Karimi, Yasmin , Evens, Andrew M. , Naik, Seema , Kamdar, Manali , Haverkos, Bradley M. , Rubinstein, P , Chaudhry, Amina, Epperla, Narendranath , Zayac, Adam S , Bock, Allison M , Ayers, Emily C , Girton, Mark , Hu, Marie , Li, Shaoying , Medeiros, L Jeffrey , Chang, Julie E , Torka, Pallawi , Smith, Stephen D , Karimi, Yasmin H , Bond, David A , Naik, Seema G , Haverkos, Bradley M , Karmali, Reem , Farooq, Umar , Vose, Julie , Rubinstein, Paul G , Olszewski, Adam J , Evens, Andrew M , Naresh, Kikkeri N , Kamdar, Manali , Epperla, Narendranath , Landsburg, Daniel J. , Medeiros, L. Jeffrey , Kurt, Habibe , Sundaram, Suchitra , Bond, David A. , Karmali, Reem , Vose, Julie M. , Chaudhry, Amina, Olszewski, Adam J.

Mayo Clinic

Blood Advances | August 27, 2024 | Volume: 8 | Issue: 20 | Pages: 5355-5364

10.1182/bloodadvances.2024013791 | PMID 39189932 Get It

Abstract Little is known about the central nervous system (CNS) risk in high-grade B-cell lymphoma, not otherwise specified (HGBL NOS). Hence, we sought to describe the rates of baseline CNS involvement, risk of CNS recurrence after primary therapy, and management strategies in HGBL NOS. In this multicenter retrospective study, we included 160 adults with newly diagnosed HGBL NOS treated between 2016 and 2021 at 20 US institutions. Eleven patients (7%) had baseline CNS involvement at diagnosis (leptomeningeal = 6, parenchymal = 4, and both = 1). Baseline CNS involvement was significantly associated only with MYC rearrangement (OR = 3.5) and testicular (in men) or female pelvic (in women) involvement (OR = 8.1). There was no significant difference in survival outcomes between patients with HGBL NOS with (median PFS = 4 years) or without (median PFS = 2.4 years) baseline CNS involvement (P = 0.45). The cumulative incidence of CNS recurrence at 3 years was 11%. Patients with baseline CNS involvement were at the highest risk (48.5% vs 8% for those without baseline CNS involvement) and were excluded from the risk factors analysis for CNS recurrence. The risk for CNS recurrence was significantly associated with blood or bone marrow involvement, CD5 expression, non–germinal center B-cell subtype, and “dual-expresser lymphoma” phenotype, however, high CNS IPI was not. The prognosis of relapsed HGBL NOS was poor, regardless of whether recurrence was systemic or limited to the CNS, and with currently available salvage strategies, including autologous transplantation and chimeric antigen receptor T-cell modalities, almost all patients with CNS recurrence ultimately succumbed to their disease.
Technical Factors Associated With the Benefit of Prophylactic Pancreatic Stent Placement During High-Risk Endoscopic Retrograde Cholangiopancreatography: A Secondary Analysis of the SVI Trial Data Set
Elmunzer, B. Joseph , Zhang, Jingwen , Coté, Gregory A. , Wani, Sachin , Shah, Raj J. , Bang, Ji Young , Varadarajulu, Shyam , Singh, Vikesh K. , Khashab, Mouen A. , Kwon, Richard S. , Scheiman, James M., Keilin, Steven , Chak, Amitabh , Slivka, Adam, Mullady, Daniel , Kushnir, Vladimir , Buxbaum, James , Keswani, Rajesh N. , Gardner, Timothy B. , Forbes, Nauzer , Rastogi, Amit, Ross, Andrew S., Law, Joanna K. , Chen, Yen‐I , Smith, Zachary L. , Petersen, Bret T. , Wang, Andrew Y. , Saltzman, John R. , Spitzer, Rebecca L., Ordiah, Collins, Spino, Cathie , Foster, Lydia D. , Durkalski‐Mauldin, Valerie, Group*, on behalf of the SVI Study, Shah, Raj , Singh, Vikesh K , Kwon, Richard S , Willingham, Field F , Chak, Amitabh , Mullady, Daniel , Forbes, Nauzer , Ross, Andrew , Law, Joanna , Chen, Yen-I , Smith, Zachary L , Serrano, Jose , Petersen, Bret, Wang, Andrew Y , Saltzman, John R , Spino, Cathie , Foster, Lydia D , Edmundowicz, Steven A. , Willingham, Field F. , Papachristou, Georgios I. , Yachimski, Patrick , Barkun, Alan , Serrano, José , Group*, on behalf of the SVI Study

Mayo Clinic

American Journal of Gastroenterology | August 27, 2024 | Volume: 120 | Issue: 4 | Pages: 811-815

10.14309/ajg.0000000000003052 | PMID 39207308 Get It

INTRODUCTION: Prophylactic pancreatic stent placement (PSP) is effective for preventing pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP) in high-risk cases, but the optimal technical approach to this intervention remains uncertain. METHODS: In this secondary analysis of 787 clinical trial patients who underwent successful stent placement, we studied the impact of (i) whether pancreatic wire access was achieved for the sole purpose of PSP or naturally during the conduct of the case, (ii) the amount of effort expended on PSP, (iii) stent length, (iv) stent diameter, and (v) guidewire caliber. We used logistic regression models to examine the adjusted association between each technical factor and post-ERCP pancreatitis (PEP). RESULTS: Ninety-one of the 787 patients experienced PEP. There was no clear association between PEP and whether pancreatic wire access was achieved for the sole purpose of PSP (vs occurring naturally; odds ratio [OR] 0.82, 95% confidence interval [CI] 0.37–1.84), whether substantial effort expended on stent placement (vs nonsubstantial effort; OR 1.58, 95% CI 0.73–3.45), stent length (>5 vs ≤5 cm; OR 1.01, 95% CI 0.63–1.61), stent diameter (≥5 vs <5 Fr; OR 1.13, 95% CI 0.65–1.96), or guidewire caliber (0.035 vs 0.025 in; 0.83, 95% CI 0.49–1.41). DISCUSSION: The 5 modifiable technical factors studied in this secondary analysis of large-scale randomized trial data did not appear to have a strong impact on the benefit of prophylactic PSP in preventing PEP after high-risk ERCP. Within the limitations of post hoc subgroup analysis, these findings may have important implications in procedural decision making and suggest that the benefit of PSP is robust to variations in technical approach.
Inflammation, physical activity, and disease-free survival in stage III colon cancer: Cancer and Leukemia Group B–Southwest Oncology Group 80702 (Alliance)
Brown, Justin C. , Shi, Qian , Couture, Félix , Kuebler, Philip , Kumar, Pankaj , Tan, Benjamin , Krishnamurthi, Smitha , Chang, Victor T. , Goldberg, Richard M. , Shields, Anthony F. , Meyerhardt, Jeffrey A. , Brown, Justin C. , Kuebler, J. Philip , Shi, Qian , Chang, Victor T-S , Shields, Anthony F , Brown, Justin C , Meyerhardt, Jeffrey A , Ma, Chao , Goldberg, Richard M. , O’Reilly, Eileen M. , Brown, Justin C.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | August 24, 2024 | Volume: 116 | Issue: 12 | Pages: 2032-2039

10.1093/jnci/djae203 | PMID 39180477 Get It

Abstract Background Inflammation and insufficient physical inactivity contribute to individual-level risk of disease recurrence and death in stage III colon cancer. The extent to which increased inflammatory risk can be offset by sufficient physical activity remains unknown. Methods This cohort study was nested within the Cancer and Leukemia Group B (now part of the Alliance for Clinical Trials in Oncology) and Southwest Oncology Group randomized trial. Inflammatory burden was quantified by high-sensitivity C-reactive protein, interleukin-6, and soluble tumor necrosis factor-α receptor 2 after recovery from tumor resection. Physical activity was measured during and after postoperative chemotherapy. The primary endpoint was disease-free survival. Results The 3-year disease-free survival rate was 88.4% among patients with low inflammation and sufficient physical activity (referent group for all comparisons), 84.9% with low inflammation and insufficient physical activity (absolute risk difference = −3.5 percentage points, 95% confidence interval [CI] = −11.3 to 4.3; P = .38), 78.0% with intermediate inflammation and insufficient physical activity (absolute risk difference = −10.4 percentage points, 95% CI = −17.4 to −3.3; P = .007), and 79.7% with high inflammation and insufficient physical activity (absolute risk difference = −8.7 percentage points, 95% CI = −15.7 to −1.6; P = .022). In contrast, the 3-year disease-free survival rate was 87.3% among patients with intermediate inflammation and sufficient physical activity (absolute risk difference = −1.1 percentage points, 95% CI = −7.5 to 5.3; P = .74) and 84.4% with high inflammation and sufficient physical activity (absolute risk difference = −4.0 percentage points, 95% CI = −12.3 to 4.3; P = .34). Conclusion In this observational study of stage III colon cancer patients, physical activity was associated with improved disease-free survival despite high inflammation. Patients with intermediate or high inflammation who were physically active had disease-free survival rates that were not statistically significantly different from those with low inflammation.
Comparison of combined intravenous and intra-arterial thrombolysis with intravenous thrombolysis alone in stroke patients undergoing mechanical thrombectomy: a propensity-matched analysis
Elawady, Sameh Samir , Kasem, Rahim Abo , Mulpur, Bhageeradh , Matsukawa, Hidetoshi , Sowlat, Mohammad‐Mahdi , Orscelik, Atakan , Nawabi, Noah, Isidor, Julio , Maier, Ilko , Jabbour, Pascal , Kim, Joon‐Tae , Wolfe, Stacey Q , Rai, Ansaar, Starke, Robert M. , Psychogios, Marios‐Nikos, Yoshimura, Shinichi , Alaraj, Ali , Ezzeldin, Mohamad , Tanweer, Omar , Polifka, Adam , Siddiqui, Fazeel , Crosa, Roberto , Brinjikji, Waleed , Moss, Mark, Dağlıoğlu, Ergün , Williamson, Richard A., Kan, Peter , Chowdhry, Shakeel , Altschul, David , Spiotta, Alejandro M , Abo Kasem, Rahim , Matsukawa, Hidetoshi , Sowlat, Mohammad-Mahdi , Orscelik, Atakan , Maier, Ilko , Jabbour, Pascal , Wolfe, Stacey Quintero , Cuellar-Saenz, Hugo H , Howard, Brian M , Alaraj, Ali , Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Grandhi, Ramesh , Crosa, Roberto , Matouk, Charles , Brinjikji, Waleed , Navia, Pedro , Kan, Peter , De Leacy, Reade , Altschul, David J , Spiotta, Alejandro M , Levitt, Michael R , Cunningham, Conor M. , Jabbour, Pascal , Rai, Ansaar , Samaniego, Edgar A , Cuellar, Hugo , Alawieh, Ali , Romano, Daniele Giuseppe , Fragata, Isabel , Grandhi, Ramesh , Matouk, Charles , Park, Min S. , Williamson, Richard, Navía, Pedro , Leacy, Reade De , Levitt, Michael R. , Goyal, Nitin

Mayo Clinic

Journal of NeuroInterventional Surgery | August 23, 2024 | Volume: 17 | Issue: e2 | Pages: e261-e268

10.1136/jnis-2024-021975 | PMID 39179373 Get It

Background A combination of intravenous (IVT) or intra-arterial (IAT) thrombolysis with mechanical thrombectomy (MT) for acute ischemic stroke due to large vessel occlusion (AIS-LVO) has been investigated. However, there is limited data on patients who receive both IVT and IAT compared with IVT alone before MT. Methods STAR data from 2013 to 2023 was utilized. We performed propensity score matching between the two groups. The primary outcomes were symptomatic intracranial hemorrhage (sICH) and 90-day modified Rankin Scale (mRS) score 0–2. Secondary outcomes included successful recanalization (modified treatment in cerebral infarction (mTICI) ≥2B, ≥2C), early neurological improvement, any intracranial hemorrhage (ICH), and 90-day mortality. Results A total of 2454 AIS-LVO patients were included. Propensity matching yielded 190 well-matched patients in each group. No significant differences were observed between the groups in either ICH or sICH (odds ratio (OR): 0.80, 95% confidence interval (CI) 0.51–1.24, P=0.37; OR: 0.60, 95% CI 0.29 to 1.24, P=0.21, respectively). Rates of successful recanalization and early neurological improvement (ENI) were significantly lower in MT+IVT + IAT. mRS 0–1 and mortality were not significantly different between the two groups. However, the MT+IVT + IAT group demonstrated superior rates of good functional outcomes (90-day mRS 0–1) compared with patients in the MT+IVT group who had mTICI ≤2B, (OR: 2.18, 95% CI 1.05 to 3.99, P=0.04). Conclusion The combined use of IAT and IVT thrombolysis in AIS-LVO patients undergoing MT is safe. Although the MT+IVT+ IAT group demonstrated lower rates of recanalization and early neurological improvement, long-term functional outcomes were favorable in this group suggesting a potential delayed benefit of IAT.
Stereotactic Radiosurgery With Versus Without Neoadjuvant Endovascular Embolization for Brain Arteriovenous Malformations With Associated Intracranial Aneurysms
Becerril‐Gaitan, Andrea , Nguyen, Justin H. , Lee, Cheng‐Chia , Ding, Dale , Woo, Shiao Y. , Warnick, Ronald E. , Feliciano, Caleb , Rodriguez-Mercado, R, Cockroft, Kevin M. , Simon, Scott D. , Lee, John, Sheehan, Jason P. , Chen, Ching-Jen , Ding, Dale , Nguyen, Justin, Cifarelli, Christopher P. , Liščák, Roman , Williams, Brian J. , Yusuf, Mehran Behruj , Trifiletti, Daniel M. , Mathieu, David , Kondziolka, Douglas , Lee, John, Chen, Ching‐Jen

Mayo Clinic

Neurosurgery | August 22, 2024 | Volume: 96 | Issue: 4 | Pages: 787-793

10.1227/neu.0000000000003152 | PMID 39171929 Get It

BACKGROUND AND OBJECTIVES: Stereotactic radiosurgery (SRS) with neoadjuvant embolization is a treatment strategy for brain arteriovenous malformations (AVMs), especially for those with large nidal volume or concomitant aneurysms. The aim of this study was to assess the effects of pre-SRS embolization in AVMs with an associated intracranial aneurysm (IA). METHODS: The International Radiosurgery Research Foundation AVM database from 1987 to 2018 was retrospectively reviewed. SRS-treated AVMs with IAs were included. Patients were categorized into those treated with upfront embolization (E + SRS) vs stand-alone SRS (SRS). Primary end point was a favorable outcome (AVM obliteration + no permanent radiation-induced changes or post-SRS hemorrhage). Secondary outcomes included AVM obliteration, mortality, follow-up modified Rankin Scale, post-SRS hemorrhage, and radiation-induced changes. RESULTS: Forty four AVM patients with associated IAs were included, of which 23 (52.3%) underwent pre-SRS embolization and 21 (47.7%) SRS only. Significant differences between the E + SRS vs SRS groups were found for AVM maximum diameter (1.5 ± 0.5 vs 1.1 ± 0.4 cm 3 , P = .019) and SRS treatment volume (9.3 ± 8.3 vs 4.3 ± 3.3 cm 3 , P = .025). A favorable outcome was achieved in 45.4% of patients in the E + SRS group and 38.1% in the SRS group ( P = .625). Obliteration rates were comparable (56.5% for E + SRS vs 47.6% for SRS, P = .555), whereas a higher mortality rate was found in the SRS group (19.1% vs 0%, P = .048). After adjusting for AVM maximum diameter, SRS treatment volume, and maximum radiation dose, the likelihood of achieving favorable outcome and AVM obliteration did not differ between groups ( P = .475 and P = .820, respectively). CONCLUSION: The likelihood of a favorable outcome and AVM obliteration after SRS with neoadjuvant embolization in AVMs with concomitant IA seems to be comparable with stand-alone SRS, even after adjusting for AVM volume and SRS maximum dose. However, the increased mortality among the stand-alone SRS group and relatively low risk of embolization-related complications suggest that these patients may benefit from a combined treatment approach.
A narrative review of lifestyle management guidelines for metabolic dysfunction–associated steatotic liver disease
Ivancovsky‐Wajcman, Dana , Byrne, Christopher J. , Dillon, John , Brennan, Paul , Villota‐Rivas, Marcela , Younossi, Zobair M. , Allen, Alina M. , Gerber, Lynn H. , Lazarus, Jeffrey V. , Dillon, John F , Brennan, Paul N , Crespo, Javier , Lazarus, Jeffrey V , Gerber, Lynn H , Allen, Alina M , Crespo, Javier

Mayo Clinic

Hepatology | August 22, 2024 | Volume: 83 | Issue: 5 | Pages: 1303-1325

10.1097/hep.0000000000001058 | PMID 39167567 Get It

Background and Aims: Metabolic dysfunction–associated steatotic liver disease management guidelines have been published worldwide; we aimed to summarize, categorize, and compare their lifestyle intervention recommendations. Approach and Results: We searched metabolic dysfunction–associated steatotic liver disease/NAFLD management guidelines published between January 1, 2013, and June 31, 2024, through databases including PubMed/MEDLINE, Cochrane, and CINAHL. In total, 35 qualifying guidelines were included in the final analysis. Guideline recommendations were categorized into 5 domains (ie, weight reduction goals, physical activity, nutrition, alcohol, and tobacco smoking) and were ranked based on how frequently they appeared. A recommendation was defined as widely adopted if recommended in ≥24 (≥66.6%) of the guidelines. These included increasing physical activity; reducing body weight by 7%–10% to improve steatohepatitis and/or fibrosis; restricting caloric intake; undertaking 150–300 or 75–150 minutes/week of moderate or vigorous-intensity physical activity, respectively; and decreasing consumption of commercially produced fructose. The least mentioned topics, in ≤9 of the guidelines, evaluated environmental determinants of health, mental health, referring patients for psychological or cognitive behavioral therapy, using digital health interventions, and assessing patients’ social determinants of health. Conclusions: Most guidelines recommend weight reduction through physical activity and improving nutrition, as these have proven positive effects on health outcomes when sustained. However, gaps regarding mental health and the social and environmental determinants of metabolic dysfunction–associated steatotic liver disease were found. To optimize behavioral modifications and treatment, we recommend carrying out studies that will provide further evidence on social support, environmental factors, and mental health, as well as further exploring digital health interventions.
Flow cytometry assay modifications: Recommendations for method validation based on CLSI H62 guidelines
Monaghan, Sara A. , Eck, Steven , Bunting, Silvia T., Dong, Xiangyang X., Durso, Robert J., Gonneau, Christèle , Hays, Amanda , Illingworth, Andrea , League, Stacy C., Linskens, Eleni , McCausland, Megan, McCloskey, Thomas W., Rolf, Nina , Wallace, Paul K. , Litwin, Virginia , Kern, Wolfgang , Deeb, George , Nash, Veronica, Olteanu, Horatiu , Wallace, Paul K , Olteanu, Horatiu , Kern, Wolfgang , Shi, Min

Mayo Clinic

Cytometry Part B: Clinical Cytometry | August 22, 2024 | Volume: 108 | Issue: 3 | Pages: 252-266

10.1002/cyto.b.22202 | PMID 39165120 Get It

AbstractThe Clinical and Laboratory Standards Institute (CLSI) H62—Validation of Assays Performed by Flow Cytometry guideline, released in 2021, provides recommendations for platform workflow and quality system essentials, instrument setup and standardization, assay development and optimization and fit‐for‐purpose analytical method validation. In addition, CLSI H62 includes some recommendations for the validation strategies after a validated flow cytometric method has been modified. This manuscript builds on those recommendations and discusses the impact of different types of assay modifications on assay performance. Recommendations regarding which validation parameters to evaluate depending on the type of modification are provided. The impact of assay modification on the assay's intended use is discussed. When recommending minor deviations from the CLSI H62 process for a laboratory‐initiated assay revision (e.g., specimen numbers for sensitivity, specificity, or precision studies), a rationale based on expert opinion is provided with the understanding that not every laboratory, assay type, and circumstance can be comprehensively addressed in this paper. These recommendations are meant as a practical recommendation and are not intended to be restrictive, prescriptive, or understood as necessarily sufficient to meet every specific requirement from regulatory bodies (e.g., FDA or New York State Department of Health).
Cost-effectiveness of posterior lumbar interbody fusion and/or transforaminal lumbar interbody fusion for grade 1 lumbar spondylolisthesis: a 5-year Quality Outcomes Database study
Yee, Timothy J., Liles, Campbell, Johnson, Sarah E. , DiGiorgio, Anthony M. , Alan, Nima , Coric, Domagoj , Potts, Eric A. , Bisson, Erica F. , Knightly, John J. , Fu, Kai-Ming, Foley, Kevin T. , Shaffrey, Mark E., Bydon, Mohamad , Chou, Dean , Chan, Andrew K. , Meyer, Scott A., Shaffrey, Christopher I. , Slotkin, Jonathan R., Wang, Michael Y. , Haid, Regis W., Glassman, Steven D. , Virk, Michael S., Mummaneni, Praveen V., Ambati, Vardhaan , Asher, Anthony L., Virk, Michael S., Mummaneni, Praveen V. , Park, Paul

Mayo Clinic

Journal of Neurosurgery: Spine | August 17, 2024 | Volume: 41 | Issue: 5 | Pages: 596-603

10.3171/2024.5.spine24112 | PMID 39151203 Get It

OBJECTIVE Posterior lumbar interbody fusion (PLIF) and/or transforaminal lumbar interbody fusion (TLIF), referred to as "PLIF/TLIF," is a commonly performed operation for lumbar spondylolisthesis. Its long-term cost-effectiveness has not been well described. The aim of this study was to determine the 5-year cost-effectiveness of PLIF/TLIF for grade 1 degenerative lumbar spondylolisthesis using prospective data collected from the multicenter Quality Outcomes Database (QOD). METHODS Patients enrolled in the prospective, multicenter QOD grade 1 lumbar spondylolisthesis module were included if they underwent single-stage PLIF/TLIF. EQ-5D scores at baseline, 3 months, 12 months, 24 months, 36 months, and 60 months were used to calculate gains in quality-adjusted life years (QALYs) associated with surgery relative to preoperative baseline. Healthcare-related costs associated with the index surgery and related reoperations were calculated using Medicare reimbursement–based cost estimates and validated using price transparency diagnosis-related group (DRG) charges and Medicare charge-to-cost ratios (CCRs). Cost per QALY gained over 60 months postoperatively was assessed. RESULTS Across 12 surgical centers, 385 patients were identified. The mean patient age was 60.2 (95% CI 59.1–61.3) years, and 38% of patients were male. The reoperation rate was 5.7%. DRG 460 cost estimates were stable between our Medicare reimbursement–based models and the CCR-based model, validating the focus on Medicare reimbursement. Across the entire cohort, the mean QALY gain at 60 months postoperatively was 1.07 (95% CI 0.97–1.18), and the mean cost of PLIF/TLIF was $31,634. PLIF/TLIF was associated with a mean 60-month cost per QALY gained of $29,511. Among patients who did not undergo reoperation (n = 363), the mean 60-month QALY gain was 1.10 (95% CI 0.99–1.20), and cost per QALY gained was $27,591. Among those who underwent reoperation (n = 22), the mean 60-month QALY gain was 0.68 (95% CI 0.21–1.15), and the cost per QALY gained was $80,580. CONCLUSIONS PLIF/TLIF for degenerative grade 1 lumbar spondylolisthesis was associated with a mean 60-month cost per QALY gained of $29,511 with Medicare fees. This is far below the well-established societal willingness-to-pay threshold of $100,000, suggesting long-term cost-effectiveness. PLIF/TLIF remains cost-effective for patients who undergo reoperation.
Predictors of patient satisfaction in the surgical treatment of cervical spondylotic myelopathy
Schüpper, Alexander J. , DiDomenico, Joseph D., Johnson, Sarah E. , Bisson, Erica F. , Bydon, Mohamad , Asher, Anthony L. , Coric, Domagoj , Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y. , Fu, Kai-Ming, Virk, Michael S. , Shaffrey, Christopher I., Gottfried, Oren N., Park, Christine , Knightly, John J. , Meyer, Scott A., Upadhyaya, Cheerag D., Shaffrey, Mark E., Chan, Andrew K. , Tumialán, Luis M. , Chou, Dean , Haid, Regis W., Mummaneni, Praveen V., Uribe, Juan S. , Turner, Jay D. , Farber, Samuel Harrison , Fu, Kai-Ming, Shaffrey, Christopher I. , Park, Paul , Mummaneni, Praveen V. , Uribe, Juan S.

Mayo Clinic

Journal of Neurosurgery: Spine | August 17, 2024 | Volume: 41 | Issue: 5 | Pages: 611-618

10.3171/2024.5.spine24326 | PMID 39151188 Get It

OBJECTIVE Patients with cervical spondylotic myelopathy (CSM) experience progressive neurological impairment. Surgical intervention is often pursued to halt neurological symptom progression and allow for recovery of function. In this paper, the authors explore predictors of patient satisfaction following surgical intervention for CSM. METHODS This is a retrospective review of prospectively collected data from the multicenter Quality Outcomes Database. Patients who underwent surgical intervention for CSM with a minimum follow-up of 2 years were included. Patient-reported satisfaction was defined as a North American Spine Society (NASS) satisfaction score of 1 or 2. Patient demographics, surgical parameters, and outcomes were assessed as related to patient satisfaction. Patient quality of life scores were measured at baseline and 24-month time points. Univariate regression analyses were performed using the chi-square test or Student t-test to assess patient satisfaction measures. Multivariate logistic regression analysis was conducted to assess for factors predictive of postoperative satisfaction at 24 months. RESULTS A total of 1140 patients at 14 institutions with CSM who underwent surgical intervention were included, and 944 completed a patient satisfaction survey at 24 months postoperatively. The baseline modified Japanese Orthopaedic Association (mJOA) score was 12.0 ± 2.8. A total of 793 (84.0%) patients reported satisfaction (NASS score 1 or 2) after 2 years. Male and female patients reported similar satisfaction rates (female sex: 47.0% not satisfied vs 48.5% satisfied, p = 0.73). Black race was associated with less satisfaction (26.5% not satisfied vs 13.2% satisfied, p < 0.01). Baseline psychiatric comorbidities, obesity, and length of stay did not correlate with 24-month satisfaction. Crossing the cervicothoracic junction did not affect satisfactory scores (p = 0.19), and minimally invasive approaches were not associated with increased patient satisfaction (p = 0.14). Lower baseline numeric rating scale neck pain scores (5.03 vs 5.61, p = 0.04) and higher baseline mJOA scores (12.28 vs 11.66, p = 0.01) were associated with higher satisfaction rates. CONCLUSIONS Surgical treatment of CSM results in a high rate of patient satisfaction (84.0%) at the 2-year follow-up. Patients with milder myelopathy report higher satisfaction rates, suggesting that intervention earlier in the disease process may result in greater long-term satisfaction.
The emerging field of viroimmunotherapy for pediatric brain tumors
García-Moure, Marc , Laspidea, Virginia , Gupta, Sumit , Khatua, Soumen , Parthasarathy, Akhila , Lang, Frederick F. , Fueyo, Juàn , Gomez‐Manzano, Candelaria , Fueyo, Juan , Gomez-Manzano, Candelaria , Gillard, Andrew Gregg , He, Jiasen , Alonso, Marta M

Mayo Clinic

Neuro-Oncology | August 16, 2024 | Volume: 26 | Issue: 11 | Pages: 1981-1993

10.1093/neuonc/noae160 | PMID 39148489 Get It

Abstract Pediatric brain tumors are the most common solid tumors in children. Even to date, with the advances in multimodality therapeutic management, survival outcomes remain dismal in some types of tumors, such as pediatric-type diffuse high-grade gliomas or central nervous system embryonal tumors. Failure to understand the complex molecular heterogeneity and the elusive tumor and microenvironment interplay continues to undermine therapeutic efficacy. Developing a strategy that would improve survival for these fatal tumors remains unmet in pediatric neuro-oncology. Oncolytic viruses (OVs) are emerging as a feasible, safe, and promising therapy for brain tumors. The new paradigm in virotherapy implies that the direct cytopathic effect is followed, under certain circumstances, by an antitumor immune response responsible for the partial or complete debulking of the tumor mass. OVs alone or combined with other therapeutic modalities have been primarily used in adult neuro-oncology. A surge in encouraging preclinical studies in pediatric brain tumor models recently led to the clinical translation of OVs with encouraging results in these tumors. In this review, we summarize the different virotherapy tested in preclinical and clinical studies in pediatric brain tumors, and we discuss the limitations and future avenues necessary to improve the response of these tumors to this type of therapy.